Osteoarthritis Pain Articles & Analysis
15 news found
In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the biomechanical and functional deficits linked to pain and instabilities of an orthopedic cause such as those associated with knee osteoarthritis, anterior knee pain, and ligament injuries. By providing a functional and objective ...
ByEmovi
“There is a significant need for new treatment options for patients who have persistent knee pain following a meniscectomy, which the NUsurface Implant may ...
“Tools that can support healthcare providers identifying biomechanical dysfunctions and quantifying the cause of pain and symptoms is a new frontier in diagnosing and treating the underlying causes of knee pain. ...
ByEmovi
Tanezumab 2.5 mg administered subcutaneously (SC) every eight weeks is being evaluated for the treatment of moderate-to-severe osteoarthritis (OA) pain in adult patients for whom use of other analgesics is ineffective or not appropriate. ...
The lack of intrinsic tissue healing capacity of cartilage leaves many people on the path to degenerative osteoarthritis, chronic pain and potential total knee replacement surgery , all of which place a significant burden on the world’s healthcare systems. ...
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel ...
“Injuries due to sports like anterior cruciate ligaments (ACL) injury, meniscus injury, and sciatic nerve injury can take an athlete out of the game they love and lead to knee osteoarthritis later in life – one of most common causes of ...
ByEmovi
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) ...
Developed by Emovi, the KneeKGTM is to the knee, what an EKG is for the heart, and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is the second leading cause of chronic pain. A knee pain survey revealed that ...
ByEmovi
All of Intecore’s Physical Therapy locations – Aliso Viejo, CA; Foothill Ranch, CA; Orange, CA; San Juan Capistrano, CA and Bremerton, WA – will launch the KneeKG™ in their clinics this week. Knee pain is the second leading cause of chronic pain. One out of five people experiences knee pain during their life due to an ...
ByEmovi
Developed by Emovi, the KneeKG is for the knee, like an EKG is for the heart and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is the second leading cause of chronic pain. One out of five people experiences knee ...
ByEmovi
KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a License and Supply Agreement with TRB Chemedica, a leading pharmaceutical and biotechnology company. KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a ...
Clinical trials registered with the FDA using the Icellator are underway for indications including osteoarthritis, diabetic leg pain, amputation site pain, craniofascial trauma, and erectile dysfunction. ...
Hayward, CA, USA, March 15, 2017 – Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS ...
MM-II is a novel non-opioid product that leverages the physical properties of proprietary liposomes to lubricate arthritic knee joints, thereby reducing friction and wear, consequently leading to joint pain reduction. MM-II is an intra-articular biolubricant injection which is being developed to provide symptomatic relief of mild-to-moderate osteoarthritis ...